197 related articles for article (PubMed ID: 35913658)
1. Current Considerations in the Treatment of Grade 3 Gliomas.
Jo J; Schiff D
Curr Treat Options Oncol; 2022 Sep; 23(9):1219-1232. PubMed ID: 35913658
[TBL] [Abstract][Full Text] [Related]
2. A review of adult-type diffuse gliomas in the WHO CNS5 classification with special reference to Astrocytoma, IDH-mutant and Oligodendroglioma, IDH-mutant and 1p/19q codeleted.
Santosh V; Rao S
Indian J Pathol Microbiol; 2022 May; 65(Supplement):S14-S23. PubMed ID: 35562130
[TBL] [Abstract][Full Text] [Related]
3. Radiation and chemotherapy for high-risk lower grade gliomas: Choosing between temozolomide and PCV.
McDuff SGR; Dietrich J; Atkins KM; Oh KS; Loeffler JS; Shih HA
Cancer Med; 2020 Jan; 9(1):3-11. PubMed ID: 31701682
[TBL] [Abstract][Full Text] [Related]
4. Grade II and III Oligodendroglioma and Astrocytoma.
van den Bent MJ; Chang SM
Neurol Clin; 2018 Aug; 36(3):467-484. PubMed ID: 30072066
[TBL] [Abstract][Full Text] [Related]
5. Radio-chemotherapy improves survival in IDH-mutant, 1p/19q non-codeleted secondary high-grade astrocytoma patients.
Juratli TA; Lautenschläger T; Geiger KD; Pinzer T; Krause M; Schackert G; Krex D
J Neurooncol; 2015 Sep; 124(2):197-205. PubMed ID: 26033545
[TBL] [Abstract][Full Text] [Related]
6. Predicting 1p/19q codeletion status using diffusion-, susceptibility-, perfusion-weighted, and conventional MRI in IDH-mutant lower-grade gliomas.
Yang X; Lin Y; Xing Z; She D; Su Y; Cao D
Acta Radiol; 2021 Dec; 62(12):1657-1665. PubMed ID: 33222488
[TBL] [Abstract][Full Text] [Related]
7. CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas.
Appay R; Dehais C; Maurage CA; Alentorn A; Carpentier C; Colin C; Ducray F; Escande F; Idbaih A; Kamoun A; Marie Y; Mokhtari K; Tabouret E; Trabelsi N; Uro-Coste E; Delattre JY; Figarella-Branger D;
Neuro Oncol; 2019 Dec; 21(12):1519-1528. PubMed ID: 31832685
[TBL] [Abstract][Full Text] [Related]
8. Upfront Therapy of Aggressive/High-Risk Low-Grade Glioma: Single-Institution Outcome Analysis of Temozolomide-Based Radio-Chemotherapy and Adjuvant Chemotherapy.
Anand S; Chatterjee A; Gupta T; Panda P; Moiyadi A; Epari S; Patil V; Krishnatry R; Goda JS; Jalali R
World Neurosurg; 2021 Oct; 154():e176-e184. PubMed ID: 34245877
[TBL] [Abstract][Full Text] [Related]
9.
Zhao K; Yu P; Xue Z; Liu J; Yao A; Zhao Y; Yang F; Tian J; Xu B
Acad Radiol; 2020 Jul; 27(7):e159-e167. PubMed ID: 31607471
[TBL] [Abstract][Full Text] [Related]
10. Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline.
Mohile NA; Messersmith H; Gatson NT; Hottinger AF; Lassman A; Morton J; Ney D; Nghiemphu PL; Olar A; Olson J; Perry J; Portnow J; Schiff D; Shannon A; Shih HA; Strowd R; van den Bent M; Ziu M; Blakeley J
J Clin Oncol; 2022 Feb; 40(4):403-426. PubMed ID: 34898238
[TBL] [Abstract][Full Text] [Related]
11. Surveillance imaging frequency in adult patients with lower-grade (WHO Grade 2 and 3) gliomas.
Jo J; van den Bent MJ; Nabors B; Wen PY; Schiff D
Neuro Oncol; 2022 Jul; 24(7):1035-1047. PubMed ID: 35137214
[TBL] [Abstract][Full Text] [Related]
12. Loss of H3K27 trimethylation is frequent in IDH1-R132H but not in non-canonical IDH1/2 mutated and 1p/19q codeleted oligodendroglioma: a Japanese cohort study.
Habiba U; Sugino H; Yordanova R; Ise K; Tanei ZI; Ishida Y; Tanikawa S; Terasaka S; Sato KI; Kamoshima Y; Katoh M; Nagane M; Shibahara J; Tsuda M; Tanaka S
Acta Neuropathol Commun; 2021 May; 9(1):95. PubMed ID: 34020723
[TBL] [Abstract][Full Text] [Related]
13. Diffuse Infiltrating Oligodendroglioma and Astrocytoma.
van den Bent MJ; Smits M; Kros JM; Chang SM
J Clin Oncol; 2017 Jul; 35(21):2394-2401. PubMed ID: 28640702
[TBL] [Abstract][Full Text] [Related]
14. Clinical implications of molecular analysis in diffuse glioma stratification.
Mizoguchi M; Hata N; Kuga D; Hatae R; Akagi Y; Sangatsuda Y; Fujioka Y; Takigawa K; Funakoshi Y; Suzuki SO; Iwaki T
Brain Tumor Pathol; 2021 Jul; 38(3):210-217. PubMed ID: 34268651
[TBL] [Abstract][Full Text] [Related]
15. Gliosarcoma arising from oligodendroglioma, IDH mutant and 1p/19q codeleted.
Yasuda T; Nitta M; Komori T; Kobayashi T; Masui K; Maruyama T; Sawada T; Muragaki Y; Kawamata T
Neuropathology; 2018 Feb; 38(1):41-46. PubMed ID: 28812310
[TBL] [Abstract][Full Text] [Related]
16. Radiation Therapy for IDH-Mutant Grade 2 and Grade 3 Diffuse Glioma: An ASTRO Clinical Practice Guideline.
Halasz LM; Attia A; Bradfield L; Brat DJ; Kirkpatrick JP; Laack NN; Lalani N; Lebow ES; Liu AK; Niemeier HM; Palmer JD; Peters KB; Sheehan J; Thomas RP; Vora SA; Wahl DR; Weiss SE; Yeboa DN; Zhong J; Shih HA
Pract Radiat Oncol; 2022; 12(5):370-386. PubMed ID: 35902341
[TBL] [Abstract][Full Text] [Related]
17. Anaplastic glioma: current treatment and management.
Le Rhun E; Taillibert S; Chamberlain MC
Expert Rev Neurother; 2015 Jun; 15(6):601-20. PubMed ID: 25936680
[TBL] [Abstract][Full Text] [Related]
18. H3K27me3 immunostaining is diagnostic and prognostic in diffuse gliomas with oligodendroglial or mixed oligoastrocytic morphology.
Ammendola S; Caldonazzi N; Simbolo M; Piredda ML; Brunelli M; Poliani PL; Pinna G; Sala F; Ghimenton C; Scarpa A; Barresi V
Virchows Arch; 2021 Nov; 479(5):987-996. PubMed ID: 34165590
[TBL] [Abstract][Full Text] [Related]
19. Neuroimaging-Based Classification Algorithm for Predicting 1p/19q-Codeletion Status in
Batchala PP; Muttikkal TJE; Donahue JH; Patrie JT; Schiff D; Fadul CE; Mrachek EK; Lopes MB; Jain R; Patel SH
AJNR Am J Neuroradiol; 2019 Mar; 40(3):426-432. PubMed ID: 30705071
[TBL] [Abstract][Full Text] [Related]
20. Anaplastic Glioma: Treatment Approaches in the Era of Molecular Diagnostics.
Ruff MW; Uhm J
Curr Treat Options Oncol; 2018 Oct; 19(12):61. PubMed ID: 30361986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
